About Jecure Therapeutics
Jecure Therapeutics is a Healthcare company based in San Diego (United States) founded in 2015, and was acquired by Genentech in November 2018. Therapeutics for NASH and liver fibrosis are discovered and developed. Jecure Therapeutics has raised $18.02 million across 3 funding rounds from investors including Genentech and Versant Ventures. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Hepatic disorders. Its competitors include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune; 3 of its 3 listed competitors have raised funding.
Company details
Jecure Therapeutics was founded in 2015 in San Diego, United States, within the biotechnology sector. Focus is placed on the discovery and development of novel therapeutics targeting nonalcoholic steatohepatitis (NASH) and liver fibrosis. Operations center on a lead program featuring a proprietary small molecule inhibitor directed at an undisclosed novel target identified as a pro-inflammatory driver in NASH.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website jecuretx.com
- Social LinkedIn
- Acquired by Genentech (Nov 2018)
Funding Insights of Jecure Therapeutics
Jecure Therapeutics has successfully raised a total of $18.02M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $3 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18.02M
- Total Rounds 3
- Last Round Series A — $3M
- Investors Count 1
All 3 funding rounds of Jecure Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2018 | $3M | Series A | – | – | – |
| Dec 2017 | $15.02M | Series A | – | Versant Ventures | – |
| Jun 2015 | Seed | – | – |
2 investors in total: 2 institutional.
Investors in Jecure Therapeutics
Jecure Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Genentech and Versant Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
R&D company focused on manufacturing drugs for multiple therapeutic areas | 1976 | gene.com | San Francisco, United States |
Investor details for Jecure Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Jecure Therapeutics
1 people are tracked at Jecure Therapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Jeffrey Stafford | CEO | Leadership |
Complete people profiles for Jecure Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Jecure Therapeutics
4 dated milestones of Jecure Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Jecure Therapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $3.0M.
- Exit Acquired by Genentech.
Competitors of Jecure Therapeutics
Jecure Therapeutics has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. |
Detailed competitors of Jecure Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Jecure Therapeutics (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Jecure Therapeutics
Complete news archive for Jecure Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jecure Therapeutics
Jecure Therapeutics was founded in 2015.
Jecure Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Jecure Therapeutics is a funded company, having raised a total of $18.02M across 3 funding rounds to date.
Jecure Therapeutics was founded in 2015 in San Diego, United States, within the biotechnology sector. Focus is placed on the discovery and development of novel therapeutics targeting nonalcoholic steatohepatitis (NASH) and liver fibrosis. Operations center on a lead program featuring a proprietary small molecule inhibitor directed at an undisclosed novel target identified as a pro-inflammatory driver in NASH.
Jecure Therapeutics's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Altimmune.
Jecure Therapeutics has 2 investors. Key investors include Genentech, and Versant Ventures.
Yes. Jecure Therapeutics was acquired by Genentech in November 2018.